An institution-based non-randomised prospective study to estimate the efficacy and adverse effect profile of apremilast for moderate to severe refractory palmoplantar psoriasis
Keywords:Psoriasis, Palmoplantar, Apremilast, Adverse effect
Background: Psoriasis is an immune-mediated inflammatory papulo-squamous disorder presenting as chronic plaque, pustular, erythrodermic, nail, scalp, drug induced, inverse, guttate etc. Palmoplantar psoriasis causes significant functional, cosmetic and psychological disability. Apremilast is a relatively newer drug being PDE-4 inhibitor, having negligible adverse effects with minimum blood monitoring.
Methods: It is an institution-based, non-randomised, prospective study conducted over a period of 3 months. 42 patients of moderate to severe disease (assessed using PPPASI), refractory to conventional line of therapy (for atleast 3 months) or had contraindications for the same were selected from our Dermatology OPD. Follow up was done monthly for 6 months.
Results: 42% of the patients were good responders. 1 patient did not respond and 2 had progression of the disease. There was a decrease in the mean DLQI from a baseline of 25 to less than 15 by the end of 1st month and around 5 by the end of 6th month.60% of patients showed onset of response by the 1st month. 45% of the patients showed adverse effects, mostly being nausea followed by dizziness.
Conclusions: From our study and those in the existing literature, it can be inferred that apremilast is a promising drug for palmoplantar as well as other forms of psoriasis, especially in patients with comorbidities or treatment refractory psoriasis.
Otezla FL. an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am health Drug Benefits. 2015;8:105-10.
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583-90.
Product monograph 2017: Otezla (apremilast) tablets 10 mg, 20 mg and 30 mg. Available at: https://media. celgene.com/cpntent/uploads/sites/23/Otezla-Product -Monograph-english.pdf. Accessed on 20 November 2022.
Kushwaha AS, Repka MA, Narasimha Murthy S. A novel apremilast nail lacquer formulation for the treatment of nail psoriasis. AAPS Pharm Sci Tech. 2017;18:2949-56.
Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D. Real World data on the efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018; 32:1173-9.
Wong TH, Sinclair S, Smith B, Fraser C, Morton CA. Real world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis. Clin Exp Dermatol. 2017;42:675-6.
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral Phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: A phase III, randomised controlled trial. Br J Dermatol. 2015;173:1387-99.
Reich K, Gooderham S, Green L, Bewley A, Zhang Z, Khanskaya I, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate to severe plaque psoriasis: 52 week results from a phase IIIb, randomised, placebo-controlled trial. J Eur Acad Dermatol Venereol. 2017;31:507-17.
Armstrong A, Levi E. Real-world clinical experience with apremilast in a large US retrospective cohort study of patients with moderate to severe plaque psoriasis. J Drugs Dermatol. 2017;16:1240-5.
Stander S, Syring F, Ludwig RJ, Thaci D. Successful treatment of refractory palmoplantar Pustular Psoriasis with Apremilast: a case series. Front Med. 2020;7: 543944.
Thaci D, Kimball A, Foley P. Apremilast, an oral Phosphodiesterase 4 inhibitor, improves patient reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomised controlled trials. J Eur Acad Dermatol Venereol. 2017; 31(3):498-506.
Bissonnette R, Haydey R, Rosoph LA. Apremilast for the treatment of moderate to severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomised study. J Eur Acad Dermatol Venereol. 2018;32(3):403-10.
Eto A, Nakao M, Furue M. Three cases of palmoplantar pustulosis successfully treated with apremilast. J Dermatol. 2019;46(1):e29-30.
Crowley J, Thaci D, Joly P. Long term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for >=156 weeks from phase 2, phase 3, randomised, controlled trials. J Am Acad Dermatol. 2017;77(2):310-7.
Zhang R, Maratos-Flier E, Flier JS. Reduced adiposity and high-fat diet induced adipose inflammation in mice deficient for Phosphodiesterase 4B. Endocrinology. 2009;150(7):3076-82.
Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.
Raker VK, Becker C, Steinbrink K. The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases. Front Immunol. 2016;7:123.
Langley A, Beecker J. Management of common side effects of Apremilast. J Cutan Med Surg. 2018;22:415-21.
Strober B, Bagel J, Lebwohl M. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study. J Drugs Dermatol. 2017;16(8):801-8.
Hagberg KW, Persson R, Vasilakis-Scaramozza C. Herpes Zoster, Hepatitis C, and Tuberculosis risk with Apremilast compared to biologics, DMARDs and Corticosteroids to treat psoriasis and psoriatic arthritis. Clin Epidemiol. 2020;12:153-61.